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Intracranial Emboli
Associated With Catheter
Ablation of Atrial Fibrillation
Has the Silence Finally Been Broken?*
Jonathan S. Steinberg, MD, Suneet Mittal, MD
New York, New York
Catheter ablation has become an accepted treatment ap-
proach for drug-refractory, symptomatic atrial fibrillation
(AF). The technical aspects of the procedure have evolved,
but to a remarkable degree, the objective of the procedure is
nearly the same as when it was first introduced: the electrical
isolation of the principal trigger sites of AF, the pulmonary
veins (PVI). The procedure has an excellent success rate and
acceptable safety profile, although AF may not be perma-
nently eliminated even if response is initially complete (1).
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There are, however, a number of complications that are
associated with the procedure. One of the rare but most
dreaded complications of the procedure is systemic embo-
lism, which typically presents as a transient ischemic attack
(TIA) or stroke. The mechanism by which stroke occurs is
likely thromboembolism in the majority of instances; how-
ever, embolism of air and/or coagulum likely contributes as
well (2). To minimize embolic complications, most electro-
physiology laboratories have developed standards for pre-,
intra-, and post-procedural anticoagulation as well as man-
agement of intracardiac sheaths and catheters. Nonetheless,
the most recent worldwide survey on catheter ablation of
AF reported a 0.71% incidence of TIA and 0.23% incidence
of stroke (3). To date, the incidence of thromboembolism
has not been thought to vary with the energy source used for
ablation.
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modalities of energy delivery are being introduced, primarily
in an effort to make this complex procedure more efficient
and accessible. Two of these new entries, cryoballoon and
multielectrode phased radiofrequency (RF) pulmonary vein
ablation catheter (PVAC), in comparison to the standard
approach of RF delivery using an open irrigated tip catheter,
are the focus of inquiry in the important study of Siklo´dy et
al. (4) published in this issue of the Journal. The data are
derived from an observational series of 74 patients under-
going ablation at 3 centers in Europe; the study was stopped
prematurely when an independent ethics committee noted a
dramatically higher rate of silent brain infarction following
ablation in the PVAC group.
The patients in this study were similar to many prior
published series, although slightly older. More than 60% of
the patients had paroxysmal AF, which is typical, and the
remainder had persistent AF. All patients underwent PVI
alone without any additional linear or nonlinear left atrial
ablation. The groups were well matched. All patients had
similar pre-, intra-, and post-procedural care, including
anticoagulation, level and duration of energy delivery, and
performance of transesophageal echocardiography (TEE) to
exclude pre-existing thrombus. They did not undergo in-
tracardiac echocardiography. The 27 patients who under-
went irrigated RF ablation had lesions placed in a circum-
ferential fashion around each ipsilateral pair of PVs. The 24
patients who underwent cryoballoon ablation had balloons
sized according to TEE-measured diameters; touch-up
using a focal cryoablation catheter was performed if isolation
was not achieved with the balloon alone. The PVAC was
used in 24 patients. It is a circular mapping and ablation
system capable of duty-cycled phased unipolar and bipolar
RF delivery at low energy levels to specific electrodes or
pairs of electrodes, without internal or external irrigation.
All patients, irrespective of technique, were required to
achieve complete PVI, and indeed, all met this procedural
endpoint. Ultimate clinical outcome, that is, AF suppres-
sion, was not reported.
What is reported is a marked disparity in incidence of
new embolic events as detected by brain magnetic resonance
imaging (MRI). All patients underwent a pre-ablation (1
day prior) and a post-ablation (within 2 days) scan. New
embolic events were documented in 7.4% of irrigated RF
patients, 4.3% of cryoballoon patients, and 37.5% of PVAC
patients, statistically different among groups (p  0.003).
The PVAC patients had between 1 and 5 new lesions
(median  3) with a wide intracranial distribution, consis-
tent with an embolic source. Based on an examination by a
non-neurologist physician, all patients were asymptomatic
without overt neurological findings in the early aftermath of
ablation, although sophisticated examination and testing
were not performed. The use of cryoenergy was not immune
to silent infarction, confirming prior results (5). The use of
PVAC was the only factor predictive of new embolic events.
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important issues: 1) the safety of ablation for AF in regard
to silent brain infarcts and its long-term clinical impact; and
2) whether newer alternative techniques have unexpected
and potentially serious deleterious consequences.
It has only recently been recognized that an overt TIA or
stroke likely represents only the “tip of the iceberg” when it
comes to intracranial emboli resulting from catheter abla-
tion of AF. MRI of the brain performed within the first few
days of ablation can demonstrate clinically silent intracranial
emboli in up to 14% of patients (6,7). Although a single
embolic lesion is typically observed, some patients experi-
ence multiple emboli. Against this historical context, the
observation in this study that a median of 3 new embolic
lesions was observed in 37.5% of PVAC patients is even
more alarming. The unresolved question is the clinical
significance of these silent brain infarcts. In the present
study, there was no control group, and neither repeat MRI
nor neuropsychological testing was performed. Nonetheless,
evidence suggests that these silent infarcts may not be
benign. For example, in population-based studies, the pres-
ence of silent brain infarcts has been associated with worse
performance on neuropsychological tests, a steeper decline
in global cognitive function, and doubling of the risk of
developing dementia (8). Patients must be informed of this
risk and its uncertain consequences, and formal indications
for the ablation procedure must weigh this risk, among
others, relative to the very real symptom benefit for patients.
It is imperative that new studies focus on very compre-
hensive, sensitive and reproducible neuropsychological
testing, performed serially over at least several months
and perhaps longer, in order to examine if, when, and to
what extent these infarctions impact brain function.
Serial MRI scans would help confirm the chronicity of
the lesions. Only when armed with functional data can
the medical and patient communities properly make a
truly informed comparative assessment of treatment mo-
dalities for AF. It should be acknowledged, however, that
AF alone can cause silent cerebral embolism (9), and
superior suppression of AF versus other treatments by
ablation may in fact produce a net benefit to patients, and
thus controlled studies are critical. The final answers
regarding consequences of these events may take many
years to be fully understood.
Are these results so definitive that they have dealt a fatal
blow to the new PVAC technology? The ethics committee
prematurely terminated the study, so clearly these members
felt convinced that patient safety was jeopardized. However,
the small sample size means that the confidence intervals
around the point estimate of embolic risk (not reported by
the investigators) will be quite wide (true for all groups),
making accurate risk assessment challenging. Thus, it is
crucial to determine whether the findings reported by
Siklody et al. (4) are reproducible with different investiga-
tors and centers, using larger samples. To this point, a very
recent study by Gaita et al. has just reported virtuallyidentical rates of silent cerebral embolism (including a
several-fold higher rate for PVAC) when comparing the
same modalities of ablation in 108 patients with paroxysmal
AF (10). Although clinically apparent acute cerebral throm-
boembolic events do not appear to occur at a higher rate
than expected (11,12), it is important to take a step back and
ask whether the PVAC technology has incremental value
versus alternative approaches. These 2 compelling recent
reports indicate that this technology may have substantially
greater risk than competing energy delivery systems, and it
would be difficult to justify its use until greater clarification
regarding mechanism and long-term consequences of silent
cerebral embolism are clarified and addressed, or the find-
ings are refuted.
What potential explanation underlies a several-fold in-
crease in embolic events when using the PVAC catheter
versus other techniques? Intuitively, restricting ablation
deliveries to the fewest necessary to accomplish procedural
goals is desirable (13); however, the PVAC and irrigated RF
systems had similar cumulative energy levels. Procedure
time is important because catheter dwell time in the left
atrium exposes the patients to thrombus formation on
ablation apparatus, air entry, and the inevitable variability in
degree of anticoagulation. However, the PVAC patients
had the shortest procedures. There is a nagging concern that
reliance on duty-cycling and passive tissue cooling for
prevention of thrombus formation and charring when no
irrigation is applied during RF delivery may not in fact be
accomplished routinely. Although, only a minority had
visibly detectable material, there is no assurance that char or
thrombus had not formed and already embolized, and it is
not clear how diligent or meticulous was the search for
material adherent to the catheter. The nature of the PVAC
system promotes current density similar to conventional
electrodes and power settings (11), which in turn may
facilitate heating concentrated in small anatomic regions or
heating of blood elements if tissue contact with the elec-
trode is absent. It is unknown whether the materials of the
PVAC ablation catheter or the manipulation during the
procedure contributes to the risk as well.
The rates of silent embolic events for the irrigated RF
catheter and cryoballoon are also higher than desirable.
Should present-day practice change in any manner to take
into account the risk of these events? We suggest the
following initiatives.
1. It is a given that meticulous attention should be em-
ployed with respect to anticoagulation throughout the
ablation process, including the sheath systems typically
used. It may be valuable to test more intensive or
customized (for ablation technique) anticoagulation reg-
imens including higher activated clotting time targets,
addition of antiplatelet medications. or use of the non-
vitamin K antagonist anticoagulants as bridging or in-
traprocedure agents.
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oughly reassessed in the laboratory and with animal
models to better understand by which mechanism these
complications may occur, so that redesign could be
undertaken if warranted.
3. The routine use of intracardiac ultrasound deserves
further scrutiny as a means of early detection of throm-
bus before embolization (14).
4. Avoidance of intraprocedural cardioversion has been
suggested (7).
5. It seems premature to require that all patients undergo
pre- and post-ablation brain MRI, but a large-scale
effort, probably via a multicenter registry, must be
undertaken to more accurately depict the incidence,
infarction pattern, and risk factors of embolic events
independent of technique. One also wonders whether
other left-sided atrial and ventricular ablations are asso-
ciated with silent embolism as well.
6. It is possible that upstream filters may be required to
prevent undesirable material from reaching the cranial
circulation.
7. Finally, the inequality of distribution of events among
the different ablation techniques strongly suggests that
testing be part of the regulatory process before a new
device or system reaches the market.
There is no question that AF ablation is an important
therapeutic advance, but unintended consequences from
complex invasive procedures should be thoroughly investi-
gated and adjudicated. Our first and foremost concern must
be both short- and long-term patient safety.
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